Search
for
Sort by
Research 361–390 of 920
- Frontal fibrosing alopecia: a disease that remains enigmatic
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Hair loss and its management in children
- Selected topics in pediatric hair loss
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment
- Medical Remedies for Alopecia
- Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia
- Disorders of hair in children
- Cutaneous Drug Reaction Case Reports
- Questions and answers for clinical insights
- Abstracts from the Symposium on the Pathophysiology of Hair Growth Organized by the Institute of Dermatology at the Royal Society of Medicine, 29 October 1987
- Hair Loss in Children
- Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Janus Kinase inhibitors in dermatology: a review
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
- Focal Asymptomatic Hair Loss in an Adolescent: A Case Report
- British Hair and Nail Society
- Hair, Cutaneous Homeostasis and Stem Cell Functions
- Bilateral Trichotillomania of Eyelashes Triggered by Anxiety due to Nocturnal Enuresis: A Case Report
- Micropigmentation
- Genetic Hair Disorders: A Review
- Prostaglandin analogs for hair growth: Great Expectations
- Should hair transplantation be performed in psoriasis?
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- JAK inhibition decreases the autoimmune burden in Down syndrome